

Huntington's Disease (HD2)

A Study to Investigate the Pharmacokinetics and Pharmacodynamics of RO7234292 (RG6042) in CSF and Plasma, and Safety and Tolerability Following Intrathecal Administration in Patients With Huntington's Disease

Trial Status
Completed

Trial Runs In
2 Countries

Trial Identifier
NCT04000594 GEN-PEAK
BP40410

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

Study BP40410 is an open-label, adaptive multiple-dose clinical study designed to characterize the PK of RO7234292 (RG6042) in plasma and CSF as well as the acute time course and recovery profile of CSF mHTT lowering in response to RO7234292 (RG6042) treatment after intrathecal (IT) administration of RO7234292 (RG6042) to patients with manifest Huntington's disease (HD).

Hoffmann-La Roche
Sponsor

Phase 1
Phase

NCT04000594 GEN-PEAK BP40410
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥25 Years & ≤ 65 Years

Healthy Volunteers
No